The Board approved the re-appointment of Internal Auditor M/s. Ernst & Young LLP ('EY') for the next financial year 2026-27.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions reported strong FY2026 consolidated revenue of Rs 65.91 billion, up 29% from Rs 50.96 billion in FY2025. Consolidated profit after tax grew 36% to Rs 1,458.40 million from Rs 1,074.34 million. The Board re-appointed EY as internal auditor for FY2026-27, re-appointed three Independent Directors for a second term, and approved an acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through its subsidiary Sai Pharma Distributors. The company also allotted 7,240 equity shares under its ESOP 2023 and granted fresh 7,300 stock options. The 8th AGM is scheduled for August 19, 2026. Standalone Q4 revenue was Rs 789.32 million with PAT of Rs 134.16 million. The statutory auditors gave an unmodified opinion on both standalone and consolidated results.
The company delivered robust growth with 36% increase in consolidated PAT, indicating strong operational performance. The continuation of EY as internal auditor and re-appointment of independent directors provides governance stability. The acquisition aligns with the company's inorganic growth strategy.